Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastases in both the pre- and post-chemotherapy setting.
Prostate Carcinoma Metastatic to the Bone
DRUG: Enzalutamide|RADIATION: Radium ra 223 dichloride
Number of participants with adverse events and serious adverse events . Adverse events deemed to be related to either study medication will be followed until resolution., 30 days after the last cycle of Radium Ra 223 dichloride, which will be approximately 7 months after study enrollment
Bone pain measured by the Bone Pain Index- Short Form questionnaire, Bone Pain, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Quality of Life Questionnaire, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Time to measurable disease progression, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Time to implementation of palliative radiotherapy, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Time to analgesic (Opioid) advancements, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Time from start of Enzalutamide to PSA progression, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Changes and time to total-ALP progression will be measured by recording laboratory values, Changes and time to total-ALP progression, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Progression to additional antineoplastic therapy will be measured by tracking subject diaries and concomitant medications, Progression to additional antineoplastic therapy, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment|Performance status change will be measured by ECOG status, Performance status change, Thorughout the study and through the last follow-up visit, estimated to be 30 months after study enrollment
This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in castrate resistant (hormone-refractory) prostate cancer subjects with symptomatic bone metastasis, in both the pre- and post- chemotherapy setting.

Radium Ra 223 dichloride is approved by the US Food and Drug Administration for this indication. Enzalutamide is US Food and Drug Administration approved for this indication.

Approximately 40 subjects will be enrolled to obtain 30 evaluable subjects. All subjects will receive Radium Ra 223 dichloride every 4 weeks for a total of 6 doses over 24 weeks and concurrent Enzalutamide for a minimum duration of 24 weeks. The sponsor will provide Enzalutamide after the End of Treatment visit until the last Long Term Follow Up visit has been completed. Subjects will continue to receive Enzalutamide as long as a positive response to therapy is demonstrated. Enzalutamide may be discontinued at any time per physician discretion.

Subjects will be evaluated 30 days after the last dose of Radium Ra 223 dichloride. Including screening, the total duration of the study is 32 weeks plus every 3 month follow up visits while subjects are receiving Enzalutamide.